BioCryst Pharmaceuticals, Inc. announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO(R) (berotralstat) in Central and Eastern Europe (CEE). Under the terms of the agreement, Swixx will be responsible for commercializing ORLADEYO in 15 markets within CEE.